Combined modality therapy in non-small cell lung cancer

Charles Blanke, D. H. Johnson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Lung cancer kills more Americans annually than the next four most frequently diagnosed malignancies combined. Single-modality therapy is the standard for most cases of limited and metastatic non-small cell lung cancer, but treatment of locally advanced disease remains controversial. Historically, radiotherapy alone was used; more recent approaches include single-agent or combination chemotherapy. The combined chemoradiotherapy approach, versus single-modality chemotherapy or irradiation, has improved on survival. Investigators have also recently shown an advantage to adding chemotherapy with or without radiotherapy to definitive surgery. Better staging systems and definitions of biologic prognostic factors may help determine the optimal therapy for locally advanced non-small cell lung cancer patients.

Original languageEnglish (US)
Pages (from-to)144-149
Number of pages6
JournalCurrent Opinion in Oncology
Volume7
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

Combined Modality Therapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Drug Therapy
Biological Factors
Chemoradiotherapy
Combination Drug Therapy
Lung Neoplasms
Therapeutics
Research Personnel
Survival
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Combined modality therapy in non-small cell lung cancer. / Blanke, Charles; Johnson, D. H.

In: Current Opinion in Oncology, Vol. 7, No. 2, 1995, p. 144-149.

Research output: Contribution to journalArticle

@article{3d344308faf24241b7a32786a44b35d5,
title = "Combined modality therapy in non-small cell lung cancer",
abstract = "Lung cancer kills more Americans annually than the next four most frequently diagnosed malignancies combined. Single-modality therapy is the standard for most cases of limited and metastatic non-small cell lung cancer, but treatment of locally advanced disease remains controversial. Historically, radiotherapy alone was used; more recent approaches include single-agent or combination chemotherapy. The combined chemoradiotherapy approach, versus single-modality chemotherapy or irradiation, has improved on survival. Investigators have also recently shown an advantage to adding chemotherapy with or without radiotherapy to definitive surgery. Better staging systems and definitions of biologic prognostic factors may help determine the optimal therapy for locally advanced non-small cell lung cancer patients.",
author = "Charles Blanke and Johnson, {D. H.}",
year = "1995",
language = "English (US)",
volume = "7",
pages = "144--149",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Combined modality therapy in non-small cell lung cancer

AU - Blanke, Charles

AU - Johnson, D. H.

PY - 1995

Y1 - 1995

N2 - Lung cancer kills more Americans annually than the next four most frequently diagnosed malignancies combined. Single-modality therapy is the standard for most cases of limited and metastatic non-small cell lung cancer, but treatment of locally advanced disease remains controversial. Historically, radiotherapy alone was used; more recent approaches include single-agent or combination chemotherapy. The combined chemoradiotherapy approach, versus single-modality chemotherapy or irradiation, has improved on survival. Investigators have also recently shown an advantage to adding chemotherapy with or without radiotherapy to definitive surgery. Better staging systems and definitions of biologic prognostic factors may help determine the optimal therapy for locally advanced non-small cell lung cancer patients.

AB - Lung cancer kills more Americans annually than the next four most frequently diagnosed malignancies combined. Single-modality therapy is the standard for most cases of limited and metastatic non-small cell lung cancer, but treatment of locally advanced disease remains controversial. Historically, radiotherapy alone was used; more recent approaches include single-agent or combination chemotherapy. The combined chemoradiotherapy approach, versus single-modality chemotherapy or irradiation, has improved on survival. Investigators have also recently shown an advantage to adding chemotherapy with or without radiotherapy to definitive surgery. Better staging systems and definitions of biologic prognostic factors may help determine the optimal therapy for locally advanced non-small cell lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0028955248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028955248&partnerID=8YFLogxK

M3 - Article

C2 - 7756379

AN - SCOPUS:0028955248

VL - 7

SP - 144

EP - 149

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -